Dimerix Limited

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

15

Website

dimerix.com

Country

Australia

Exchange

ASX

Fitzroy, Australia

Dimerix Limited, a biopharmaceutical company develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease proprietary Receptor-HIT assay technology. The company is headquartered in Fitzroy, Australia.

Key Stats

52-Week Range

A$0.16A$0.67

Beta0.34

Trailing P/EN/A

Forward P/E-11.75

Trailing EPS-0.03

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceA$1.90

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.